Information Provided By:
Fly News Breaks for February 26, 2020
Feb 26, 2020 | 05:24 EDT
Piper Sandler analyst Danielle Brill is encouraged that GW Pharmaceuticals' growth in the U.S. "continues to be strong" after the company preannounced Q4 Epidiolex revs of $104.5M. Management's guidance for flat quarter-over-quarter revenues in Q1 is likely "overly conservative" as this is the first quarter of seasonal headwinds since launch, Brill tells investors in a research note. The analyst keeps a Overweight rating on GW shares with a $160 price target.
News For GWPH From the Last 2 Days
There are no results for your query GWPH